Vaccines for bluetongue.
Isolation of 8 serotypes of bluetongue virus (BTV) in Australia has led to widespread debate on how to prepare for an outbreak of bluetongue disease and the type of vaccine best suited to control bluetongue in Australia. This article describes the vaccine options under consideration by research workers and animal health administrators. The most widely discussed options are live attenuated virus, killed virus and virus-like particles (VLP) generated by recombinant baculoviruses. Attenuated virus vaccines are cheap and easy to produce and are administered in a single dose. They replicate in sheep without causing significant clinical effects and provide protection against challenge with virulent virus of the same serotype. The possibility that insects could acquire vaccine virus by feeding on vaccinated animals and transmit it to sheep or cattle cannot be eliminated. This poses a risk because attenuated viruses are teratogenic if ewes are infected in the first half of pregnancy. In addition, vaccine virus replication in insects and ruminants may lead to a reversion to virulence. Killed virus vaccines have been shown to be efficacious in small laboratory trials and cannot be transmitted to other animals in the field, but are significantly more expensive to produce than attenuated viruses and require at least 2 doses with adjuvant to elicit an immune response. More work is needed to properly assess their effectiveness and determine their cost of production. Recombinant VLP contain the 4 major structural proteins of BTV but no nucleic acid. VLP are relatively easy to isolate, but it is unlikely that the purification methods currently used in laboratories will be adapted for use commercially. Despite the enthusiasm of recent years, little commercial progress appears to have been made. Although scientific research in Australia and overseas has provided a number of options for development of bluetongue vaccines, the decisions on which to use in an outbreak are complex and will require, not only consideration of factors discussed here, but also agreement from industry and government.
Murray
P K
PK
CSIRO Australian Animal Health Laboratory, Geelong, Victoria.
Eaton
B T
BT
D000822:Animal Husbandry / Q000191:economics / Q000379:methods; D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis / Q000276:immunology; D000956:Antigens, Viral / Q000032:analysis / Q000276:immunology; D001315:Australia / Q000453:epidemiology; D001819:Bluetongue / Q000453:epidemiology / Q000276:immunology* / Q000517:prevention & control*; D001820:Bluetongue virus / Q000276:immunology; D002417:Cattle; D002418:Cattle Diseases / Q000453:epidemiology / Q000276:immunology* / Q000517:prevention & control*; D003362:Cost-Benefit Analysis; D004196:Disease Outbreaks; D005260:Female; D011247:Pregnancy; D012756:Sheep; D012757:Sheep Diseases / Q000453:epidemiology / Q000276:immunology* / Q000517:prevention & control*; D014612:Vaccines / Q000191:economics / Q000276:immunology* / Q000592:standards; D014613:Vaccines, Attenuated / Q000191:economics / Q000276:immunology / Q000592:standards; D015164:Vaccines, Inactivated / Q000191:economics / Q000276:immunology / Q000592:standards; D014614:Vaccines, Synthetic / Q000191:economics / Q000276:immunology / Q000592:standards
D000914:Antibodies, Viral; D000956:Antigens, Viral; D014612:Vaccines; D014613:Vaccines, Attenuated; D015164:Vaccines, Inactivated; D014614:Vaccines, Synthetic